J9155 Degarelix injection
Also known as: degarelix, Firmagon
Intravenous injection of degarelix, a gonadotropin-releasing hormone (GnRH) antagonist.
In Plain Language
testosterone-lowering prostate cancer treatment; hormone therapy
Clinical Context
Used for advanced prostate cancer, achieving rapid testosterone suppression without initial testosterone surge.
RVU Information
CPT J9155 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9155?
CPT J9155 (Degarelix injection) is a J Codes (Drugs) code. Intravenous injection of degarelix, a gonadotropin-releasing hormone (GnRH) antagonist.
How is J9155 administered?
CPT J9155 is administered by a healthcare provider, typically via injection or infusion. Used for advanced prostate cancer, achieving rapid testosterone suppression without initial testosterone surge. It is used by Urology, Oncology.
When is CPT J9155 used?
Used for advanced prostate cancer, achieving rapid testosterone suppression without initial testosterone surge.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.